Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bradley McGregor, M.D.

Co-Author

This page shows the publications co-authored by Bradley McGregor and Guru Sonpavde.
Connection Strength

5.151
  1. New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma. Clin Cancer Res. 2021 May 01; 27(9):2375-2377.
    View in: PubMed
    Score: 0.957
  2. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opin Investig Drugs. 2019 Oct; 28(10):821-826.
    View in: PubMed
    Score: 0.865
  3. Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. Eur Urol Focus. 2020 01 15; 6(1):14-16.
    View in: PubMed
    Score: 0.837
  4. Immunotherapy for advanced penile cancer - rationale and potential. Nat Rev Urol. 2018 Dec; 15(12):721-723.
    View in: PubMed
    Score: 0.819
  5. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Urol Oncol. 2021 Jun 20.
    View in: PubMed
    Score: 0.244
  6. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 2021 Apr 28.
    View in: PubMed
    Score: 0.242
  7. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849.
    View in: PubMed
    Score: 0.235
  8. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.223
  9. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol. 2020 10; 3(5):695-699.
    View in: PubMed
    Score: 0.209
  10. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.197
  11. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Sep 02; 157:50-58.
    View in: PubMed
    Score: 0.062
  12. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.060
  13. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
    View in: PubMed
    Score: 0.055
  14. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. Eur Urol Oncol. 2020 10; 3(5):680-686.
    View in: PubMed
    Score: 0.052
  15. JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncol. 2018 01; 19(1):5-7.
    View in: PubMed
    Score: 0.048
  16. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017 10; 72(4):557-564.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.